echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Takeda teamed up with Carmine to develop gene therapy for rare diseases using a new red-blood extravehemal platform.

    Takeda teamed up with Carmine to develop gene therapy for rare diseases using a new red-blood extravehemal platform.

    • Last Update: 2020-07-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Under the terms of the agreement, Carmine Therapeutics will receive an advance payment as research funding, as well as installments totalling more than $900 million and tiered royalties.completes the preclinical validation study, Takeda has the option to obtain project authorization and will be responsible for clinical development and commercial promotion. In addition to, Takeda has provided a $5 million convertible loan to support the development of Carmine Therapeutics' new REGENT ™ platform.Carmine Therapeutics is pioneering a new therapy based on its reGENT ™ technology, using red blood cell exostos (RBCEV) (first published in Nature Communications in 2018).the priority of this therapy is non-viral gene therapy.gene therapy or repeatable administration based on erythropoietin than adeno-associated virus (AAV) -based gene therapy significantly increased (more than 11KB) and enhanced the biological distribution of targeted tissues through red blood cell outer vesylocysis surface modification..
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.